Articles On Hera Med (ASX:HMD)

The good news keeps flowing for medical technology company, HeraMED Limited (ASX:HMD) with the company announcing today that it has entered into an agreement with leading midwife service provider, Kinderheldin GmbH. This follows news earlie...

HeraMED’s (ASX:HMD) foetal ultrasound heart rate monitor has got its long awaited green light to enter the US market and it has doubled in just a few days. The US Food and Drug Administration has approved its 510(k) application meaning it c...

Medical technology company, HeraMED Limited’s (ASX:HMD) 510(k) application (K191110) for the company’s HeraBEAT US foetal ultrasonic heart rate monitor (HeraBEAT US) has been cleared by the US Food and Drug Administration (FDA). The FDA eva...

Medical data and technology developer HeraMED (ASX: HMD) has been granted key regulatory approval for its foetal ultrasonic heart rate monitor in the US after undergoing a premarket review process for the past 6 months. The US Food and Drug...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Each Monday, Stockhead recaps which stocks are most heavily in demand by investors — running hot. The analysis is based on the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price actio...

With a vision to revolutionize the pregnancy ecosystem HeraMED Limited (ASX: HMD) – an innovative medical technology startup, provides smart pregnancy monitoring solutions for home use, against the problems associated with the reliability o...

Yesterday was an interesting day on the markets for HeraMED (ASX:HMD), the medtech platform which makes pregnancy-monitoring devices. The stock has been trading in a range between 15c and 17c in recent months. And strategically, it’s been c...

Medical technology group HeraMED Limited (ASX:HMD) has gone from strength to strength since listing on the ASX in December 2018, excelling in the area of product development and distribution, but also forging alliances with high profile med...

HeraMED (ASX:HMD) has a target market of 2 million pregnancies in 2020, 6 million in 2021 and 45 million in 2022.

Medical company Next Science (ASX:NXS) reiterated its US market focus in an investor presentation this morning. The company forecast continued revenue growth in the 2020 financial year, led by sales of its non-toxic Xbio formulations which...

Medicinal cannabis stock Althea (ASX:AGH) had a mixed bag of news for investors in its market update this morning. The company said patient numbers for its prescription medicinal cannabis products in Australia are on track to reach 4,000 by...

Australia’s Healthcare Sector is recognised as one the best in the world with significant advances in technology that help provide better ways of delivering healthcare services. However, the sector is also prone to a number of challenges li...

Time is dynamic. Business is dynamic. Change might be the only constant factor but surprisingly for the Aussie share market, some events and statuses have remained intact over the past century. A 100 years is a really long period, and to ha...

CV Check Ltd CV Check Ltd (ASX: CV1) is a leading online integrated screening and verification company which offers check products to employers, industry associations and individual customers through the CVCheck brand on its proprietary web...